Integrated services giant Downer Edi announced today that it had secured a $4.6 billion contract with the QLD Government to build and maintain 65 new trains for Brisbane. The announcement saw Downers shares rise by 2.41%, trading at $4.035 per share.
Medibank [ASX:MPL] Faces $250 Million Penalty for Data Breach
Medibank faces a $250 million capital reserve requirement as punishment by the APRA for last October’s massive data breach in which the data of 9.7 million customers was stolen. Shares have remained resilient to the news, up by 1.71%, trading at $3.56 per share.
Best & Less [ASX:BST] in the Spotlight During Whirlwind Week
Best & Less Group Holdings made news by announcing softening trading conditions as total sales went down by 11.7%. In response, BST began clearing winter stock to meet current demand and maintain inventory quality.
Rio Tinto [ASX:RIO] makes $800 million investment in US copper
Today, Rio Tinto announced that it will invest more than US$800 million (AU$1.18 billion) into its Kennecott operation. With the investment, RIO plans to increase copper production, expand its underground mine and upgrade processing at its new smelter.
TPG [ASX:TPG] Shares Down Minus 6.6% as Tribunal Blocks $1.8 Billion Telstra [ASX:TLS] – TPG Deal
Today, the ACCC Tribunal blocked an appeal by Telstra and TPG for the proposed MOCN deal between the two. The regional network deal was worth approximately $1.8 billion and would have seen the two telcos share network assets in direct competition with Optus.
Avita Medical [ASX:AVH] Gains FDA Approval of RECELL Product for Vitiligo Patients
Avita Medical shares are down by 4.2% despite positive news as the company announces FDA approval of its breakthrough RECELL skin repair system for vitiligo patients.
Biome Australia [ASX:BIO] Surpasses $7 Million FY23 Sales Revenue Target
Biome Australia shares are up by 16.18% after news FY23 sales revenue target of $7 million has been hit with half a month of trading remaining in the quarter. This is after their flagship Activated Probiotics product range finds interest through distribution channels growth throughout Australia, the UK, and NZ.
